Humacyte's ATEV Meets Phase 3 Superiority Endpoint for Dialysis Access in Women; Plans FDA BLA Filing
HUMA has more than doubled off its 52-week low of $0.547.
Summary
Humacyte reported positive Phase 3 clinical trial results for its ATEV product in female dialysis patients, meeting its primary superiority endpoint and showing reduced infections, with plans to file a supplemental BLA with the FDA.
Key Events · Product Development and Regulatory · HUMA
-
ATEV Meets Primary Endpoint
The acellular tissue engineered vessel (ATEV) met the primary superiority endpoint in the V012 Phase 3 study for arteriovenous access in female patients requiring hemodialysis.
-
Superior Catheter-Free Days
ATEV patients experienced an average of 91 more catheter-free days compared to autologous arteriovenous (AV) fistula, the current standard of care (p=0.00070).
-
Reduced Infections
ATEV patients incurred 17 fewer dialysis access infections per 100 patient-years compared to AV fistula, demonstrating a favorable safety profile with no new or unexpected safety signals.
-
Supplemental BLA Filing Planned
Humacyte plans to file a supplemental Biologic License Application (BLA) with the FDA during the second half of 2026, targeting adult patients with end-stage kidney disease at increased risk of AV fistula maturation failure.
Analysis · HUMA · Life Sciences
Humacyte announced highly positive interim results from its Phase 3 clinical trial (V012) for its acellular tissue engineered vessel (ATEV) in female dialysis patients. The ATEV demonstrated superior catheter-free days and significantly fewer infections compared to the standard of care. This is a critical development for the company, which has recently faced financial challenges including a going concern warning and dilutive offerings. The successful trial outcome provides a strong positive signal for future product approval and commercialization, potentially addressing a significant unmet medical need and improving the company's long-term viability.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 40.2% of the 376 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HUMA was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $297.5M. The 52-week trading range was $0.55 to $2.84. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.